Phospho-BMX (Tyr566) Antibody

What is Phospho-BMX (Tyr566) Antibody and what does it detect?

Phospho-BMX (Tyr566) Antibody is a specialized immunological reagent designed to recognize the BMX protein exclusively when it is phosphorylated at tyrosine residue 566. BMX (also known as Epithelial and endothelial tyrosine kinase or ETK) belongs to the Tec kinase family of non-receptor tyrosine kinases and plays important roles in multiple signal transduction pathways, particularly the Stat pathway. The antibody employs high-affinity binding to detect the conformational change that occurs when BMX is activated through phosphorylation at this specific site. This phosphorylation represents a critical regulatory mechanism that influences BMX's enzymatic activity and its interactions with downstream signaling partners. The antibody was generated using a synthetic peptide immunogen derived from human ETK surrounding the Tyr566 phosphorylation site (amino acid range: 532-581), ensuring its specificity for this particular phosphorylation event .

Which experimental applications can Phospho-BMX (Tyr566) Antibody be used for?

Phospho-BMX (Tyr566) Antibody has been validated for multiple experimental applications, making it a versatile tool for investigating BMX signaling across different research contexts. Western blotting represents one primary application, where the antibody can detect the phosphorylated form of BMX in cell or tissue lysates with recommended dilutions ranging from 1:500 to 1:2000, allowing for semi-quantitative analysis of BMX activation states in response to various stimuli. Immunohistochemistry on paraffin-embedded sections (IHC-P) offers visualization of phosphorylated BMX in tissue contexts at dilutions between 1:100 and 1:300, enabling spatial resolution of BMX activation in complex tissues. ELISA applications provide quantitative measurement of phosphorylated BMX at recommended dilutions of approximately 1:10000, suitable for high-throughput screening approaches. Additionally, the monoclonal variant has been validated for immunofluorescence at dilutions between 1:50 and 1:200, allowing for subcellular localization studies of activated BMX .

What are the recommended storage conditions for Phospho-BMX (Tyr566) Antibody?

Optimal storage of Phospho-BMX (Tyr566) Antibody requires careful attention to temperature conditions to maintain antibody integrity and specificity over time. For long-term storage, the antibody should be maintained at -20°C, where it remains stable for approximately one year under proper conditions. For frequent use and short-term storage of up to one month, the antibody can be kept at 4°C to avoid repeated freeze-thaw cycles that may compromise antibody performance. The antibody is supplied in a stabilizing buffer consisting of PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide, which helps maintain protein structure and prevent microbial contamination during storage. Researchers should take particular care to avoid repeated freeze-thaw cycles, as these can lead to protein denaturation, aggregation, and loss of binding affinity that ultimately reduce experimental reproducibility and reliability. When handling the antibody, aliquoting upon first thaw is recommended to minimize freeze-thaw events and preserve antibody functionality for maximum shelf life .

What are the recommended dilutions for different applications?

Determining the optimal dilution for Phospho-BMX (Tyr566) Antibody is critical for achieving specific signal detection while minimizing background noise across different experimental applications. For Western blot analysis, the recommended dilution range spans from 1:500 to 1:2000, with the optimal concentration dependent on protein abundance, sample type, and detection method employed. Researchers should establish titration curves to determine the ideal concentration that maximizes specific signal while minimizing background for their particular experimental system. For immunohistochemistry on paraffin-embedded tissues (IHC-P), a dilution range of 1:100 to 1:300 is recommended, with optimization potentially necessary based on tissue fixation methods, antigen retrieval protocols, and detection systems. ELISA applications typically require more dilute antibody preparations, with recommendations suggesting a 1:10000 dilution to achieve optimal signal-to-noise ratios in this highly sensitive assay format. For immunofluorescence applications, the monoclonal version of the antibody performs optimally at dilutions between 1:50 and 1:200, allowing for visualization of subcellular localization patterns of phosphorylated BMX. Regardless of application, initial experiments should include a range of dilutions to empirically determine the optimal concentration for each specific experimental system .

How can specificity of Phospho-BMX (Tyr566) Antibody be validated?

Validating the specificity of Phospho-BMX (Tyr566) Antibody is essential for ensuring accurate interpretation of experimental results and can be accomplished through multiple complementary approaches. One definitive validation method involves using a blocking peptide competition assay, where pre-incubation of the antibody with the phosphorylated immunogenic peptide should abolish specific signal in Western blot, immunohistochemistry, or other applications. This approach was demonstrated in the validation images provided by manufacturers, where signal disappearance following phospho-peptide blocking confirms phospho-specificity. Additionally, researchers should compare detection in samples with induced phosphorylation (e.g., serum-stimulated cells, as demonstrated in the HeLa cell lysates treated with 20% serum for 15 minutes) versus untreated controls or samples treated with phosphatase to remove phosphorylation. Genetic approaches using CRISPR/Cas9 to create BMX knockout cell lines or cells expressing a Y566F mutant form of BMX (preventing phosphorylation at this residue) provide rigorous negative controls to confirm antibody specificity. Finally, comparing detection patterns across multiple application platforms (WB, IHC, IF) should yield consistent results regarding the molecular weight, localization, and regulation of phosphorylated BMX, further supporting antibody specificity .

What controls should be included when using Phospho-BMX (Tyr566) Antibody?

Implementing appropriate controls when using Phospho-BMX (Tyr566) Antibody is crucial for experimental rigor and data interpretation, requiring both positive and negative controls tailored to phospho-specific detection. Positive controls should include samples known to express phosphorylated BMX at Tyr566, such as serum-stimulated epithelial cell lines (HeLa cells treated with 20% serum for 15 minutes as shown in validation data) or other cell types with activated BMX signaling pathways. Negative controls should include unstimulated cells where BMX phosphorylation is minimal or absent, as well as samples treated with lambda phosphatase to enzymatically remove phosphate groups. Loading controls detecting total BMX protein (using a non-phospho-specific BMX antibody) should be run in parallel to distinguish between changes in phosphorylation status versus changes in total protein expression. Peptide competition controls, where the antibody is pre-incubated with the phosphorylated immunogenic peptide before application, demonstrate phospho-specificity when signal is abolished. For immunohistochemistry or immunofluorescence applications, additional controls should include secondary antibody-only staining to identify any non-specific binding of detection reagents, as well as isotype controls using non-specific IgG from the same host species as the primary antibody .

How should samples be prepared for optimal detection with Phospho-BMX (Tyr566) Antibody?

Sample preparation is a critical determinant of successful phospho-protein detection, requiring special considerations to preserve the phosphorylation state of BMX at Tyr566 throughout the experimental workflow. Cells or tissues should be lysed in buffers containing phosphatase inhibitors (e.g., sodium fluoride, sodium orthovanadate, β-glycerophosphate, and phosphatase inhibitor cocktails) to prevent dephosphorylation during sample processing. For Western blotting applications, proteins should be denatured in sample buffer containing SDS and reducing agents like β-mercaptoethanol or DTT, with minimal heating time to avoid potential dephosphorylation while ensuring complete denaturation. When preparing tissue samples for immunohistochemistry, rapid fixation is essential to preserve phospho-epitopes, with formalin fixation followed by paraffin embedding (FFPE) being the most common approach, though overfixation should be avoided as it can mask epitopes. Antigen retrieval methods, particularly heat-induced epitope retrieval in citrate buffer (pH 6.0) or EDTA buffer (pH 9.0), are typically required for FFPE samples to unmask phospho-epitopes that may be obscured during fixation. For immunofluorescence, cells should be quickly fixed with paraformaldehyde (typically 4%) for shorter durations (10-15 minutes) to balance structural preservation with epitope accessibility, followed by permeabilization with mild detergents like 0.1-0.5% Triton X-100 or 0.05% saponin .

How can Phospho-BMX (Tyr566) Antibody be used to study signal transduction pathways?

Phospho-BMX (Tyr566) Antibody serves as a powerful tool for investigating signal transduction pathways by enabling researchers to monitor the activation state of BMX in response to various stimuli and cellular contexts. To study pathway activation kinetics, researchers can perform time-course experiments where cells are stimulated with growth factors, cytokines, or other agonists, followed by Western blot analysis with the phospho-specific antibody to determine the temporal profile of BMX activation. Co-immunoprecipitation experiments using the phospho-antibody can identify proteins that specifically interact with the activated form of BMX, helping to map downstream effectors and pathway components that recognize the phosphorylated state. When combined with inhibitors targeting upstream kinases or parallel signaling pathways, the antibody can help delineate the hierarchical organization of signaling networks by determining which pathways are required for BMX phosphorylation at Tyr566. Multiplex immunofluorescence or immunohistochemistry using Phospho-BMX (Tyr566) Antibody alongside antibodies targeting other phosphorylated signaling molecules can reveal spatial relationships and co-activation patterns within intact cells or tissues, providing insights into compartmentalized signaling events. Additionally, the antibody can be employed in high-throughput screening approaches using cell-based assays to identify novel compounds or genetic factors that modulate BMX phosphorylation, potentially revealing new regulatory mechanisms or therapeutic targets .

What approaches can be used to investigate BMX phosphorylation in cancer research?

BMX phosphorylation has significant implications in cancer biology, and researchers can employ multiple complementary approaches using Phospho-BMX (Tyr566) Antibody to investigate its role in oncogenic processes. Tissue microarray analysis using immunohistochemistry with the phospho-specific antibody can evaluate BMX activation across large cohorts of patient samples, enabling correlation with clinical parameters such as tumor stage, grade, therapeutic response, and patient survival to establish prognostic or predictive value. Cell line panels representing different cancer subtypes can be screened by Western blotting to identify cancer types with constitutive BMX phosphorylation, potentially revealing cancer-specific dependencies on this signaling pathway. Functional studies combining genetic manipulation (siRNA knockdown, CRISPR knockout, or overexpression of wild-type versus phospho-mutant BMX) with phenotypic assays measuring proliferation, migration, invasion, or drug resistance can establish causal relationships between BMX phosphorylation and cancer hallmarks. Phosphoproteomic approaches integrating mass spectrometry with immunoprecipitation using the phospho-specific antibody can identify the broader signaling network affected by BMX activation in cancer cells, revealing potential combinatorial therapeutic targets. In vivo studies in mouse models of cancer using the antibody for tissue analysis can connect BMX phosphorylation status with tumor development, progression, metastasis, and response to therapy in physiologically relevant contexts that incorporate tumor microenvironment interactions .

How can false positive and false negative results be minimized when using Phospho-BMX (Tyr566) Antibody?

Minimizing false positive and false negative results when using Phospho-BMX (Tyr566) Antibody requires meticulous attention to technical details and implementation of stringent validation protocols throughout the experimental workflow. To reduce false positives, antibody specificity should be rigorously confirmed using peptide competition assays, where pre-incubation with the phosphorylated immunogenic peptide should abolish specific signals while a non-phosphorylated version of the same peptide should not affect detection. Cross-reactivity with structurally similar phospho-epitopes on other proteins should be assessed in BMX-deficient samples (knockout or knockdown), particularly in applications like immunohistochemistry where the protein context is more complex. To minimize false negatives, phosphatase inhibitors (sodium orthovanadate, sodium fluoride, β-glycerophosphate) must be included in all buffers during sample preparation to prevent dephosphorylation of the target epitope. Optimization of antigen retrieval methods for fixed tissues is essential, as insufficient retrieval can mask phospho-epitopes and lead to false negative results even when the phosphorylated protein is present. When analyzing signaling events, positive controls consisting of samples known to contain phosphorylated BMX (such as serum-stimulated cells) should be included to confirm that the detection system is functioning properly. For quantitative applications, standard curves with recombinant phosphorylated BMX protein can establish the linear detection range and prevent misinterpretation of results from samples with signal outside this range .

What alternative methods can complement antibody-based detection of phosphorylated BMX?

While Phospho-BMX (Tyr566) Antibody provides a specific and sensitive means of detecting BMX phosphorylation, complementary approaches can provide orthogonal validation and additional mechanistic insights beyond antibody-based detection alone. Mass spectrometry-based phosphoproteomics offers an antibody-independent method to identify and quantify BMX phosphorylation sites, including Tyr566, while simultaneously providing information about other phosphorylation events on BMX and interacting proteins. Kinase activity assays using recombinant BMX protein can measure the functional consequences of Tyr566 phosphorylation on catalytic activity, providing a link between the phosphorylation event and enzymatic function. Proximity ligation assays (PLA) combining antibodies against BMX and its binding partners can visualize protein interactions that are dependent on the phosphorylation state with high spatial resolution in situ. Genetic approaches using site-directed mutagenesis to generate phosphomimetic (Y566E) or phospho-deficient (Y566F) BMX mutants enable functional studies that directly test the causative role of this phosphorylation site in various cellular processes. FRET-based biosensors incorporating BMX protein domains can provide real-time visualization of BMX conformational changes and interactions associated with phosphorylation in living cells. Computational modeling using protein structure prediction algorithms can generate hypotheses about how Tyr566 phosphorylation affects protein conformation and interaction surfaces, guiding experimental designs to test specific mechanisms .

How should phosphorylation of BMX at Tyr566 be interpreted in different cellular contexts?

Interpretation of BMX phosphorylation at Tyr566 must consider the specific cellular context, as its significance can vary substantially across different cell types, tissues, and physiological or pathological states. In epithelial and endothelial cells, where BMX is predominantly expressed (reflected in its alternative name ETK - Epithelial and endothelial tyrosine kinase), phosphorylation at Tyr566 typically indicates activation in response to growth factors, cytokines, or cellular stress, potentially promoting processes such as proliferation, migration, or survival depending on the specific microenvironmental cues present. In cancer cells, constitutive phosphorylation may indicate dysregulated activation contributing to oncogenic signaling, whereas inducible phosphorylation might reflect intact regulatory mechanisms that could be targeted therapeutically. When analyzing BMX phosphorylation in tissues, the cellular heterogeneity must be considered, as the signal may originate from specific subpopulations rather than uniformly across all cells, necessitating co-staining with cell type-specific markers for accurate interpretation. Temporal dynamics are equally important, as transient versus sustained phosphorylation may trigger different downstream effects through feedback mechanisms and adaptation processes that evolve over time. Additionally, researchers should consider that Tyr566 phosphorylation is just one of multiple phosphorylation events on BMX, and its relationship with other phosphorylation sites (such as those in the activation loop or other regulatory domains) provides a more complete picture of BMX activation status and signaling capacity .

What is the relationship between BMX phosphorylation and other signaling molecules?

BMX phosphorylation at Tyr566 exists within a complex network of signaling interactions, functioning both as a consequence of upstream activators and as a driver of downstream effector pathways. As a member of the Tec family of non-receptor tyrosine kinases, phosphorylated BMX interacts with the STAT (Signal Transducer and Activator of Transcription) pathway, where its kinase activity contributes to STAT phosphorylation and subsequent transcriptional regulation of genes involved in proliferation, differentiation, and survival. The PH-like domain of BMX mediates membrane targeting through binding to phosphatidylinositol 3,4,5-triphosphate (PIP3), indicating a functional relationship with PI3K signaling that generates these lipid messengers in response to receptor activation. The SH2 domain of BMX, which binds to tyrosine-phosphorylated proteins, enables interactions with various activated receptors and scaffolding proteins, placing BMX at the crossroads of multiple signaling cascades including those initiated by growth factor receptors, cytokine receptors, G-protein coupled receptors, and integrins. Experimental approaches to map these relationships include co-immunoprecipitation studies using Phospho-BMX (Tyr566) Antibody followed by mass spectrometry to identify binding partners specific to the phosphorylated state, as well as functional studies using pathway-specific inhibitors to determine which signaling cascades are upstream or downstream of BMX phosphorylation in particular cellular contexts .

How can quantitative analysis of BMX phosphorylation be performed accurately?

Accurate quantitative analysis of BMX phosphorylation at Tyr566 requires methodological rigor and appropriate normalization strategies to account for technical and biological variables across experimental conditions. For Western blot quantification, densitometric analysis should incorporate standard curves using recombinant phosphorylated BMX protein to ensure measurements fall within the linear detection range of the antibody, while normalization to total BMX levels (detected with a phosphorylation-independent antibody) distinguishes between changes in phosphorylation status versus changes in total protein expression. ELISA-based approaches offer greater sensitivity and throughput for quantification, with sandwich ELISA formats using capture antibodies against total BMX and detection with Phospho-BMX (Tyr566) Antibody providing a direct measurement of the phosphorylated fraction. Quantitative immunofluorescence or immunohistochemistry requires careful control of all variables affecting signal intensity, including fixation time, antibody concentration, incubation periods, and detection reagents, along with inclusion of reference standards on each slide to normalize for slide-to-slide variations. Phospho-flow cytometry combining Phospho-BMX (Tyr566) Antibody with flow cytometric analysis enables single-cell quantification of BMX phosphorylation across heterogeneous populations, revealing subpopulation-specific responses that might be masked in bulk analyses. For all quantitative applications, statistical analysis should account for biological and technical replicates, with appropriate tests for significance and consideration of effect sizes rather than merely p-values to determine the biological importance of observed differences in phosphorylation levels .

What are the implications of BMX phosphorylation in disease models?

BMX phosphorylation at Tyr566 has significant implications across various disease models, particularly in cancer, cardiovascular disease, and inflammatory conditions where altered signaling pathways contribute to pathogenesis. In cancer models, phosphorylated BMX has been implicated in promoting tumor cell survival, proliferation, migration, and therapeutic resistance across multiple cancer types, with tissue-specific contexts determining the precise oncogenic mechanisms involved. The demonstration of BMX phosphorylation in thyroid gland tissues in the validation data suggests potential roles in thyroid pathophysiology, warranting investigation in models of thyroid disorders including hyperplasia, autoimmune conditions, and malignancies. In cardiovascular disease models, BMX phosphorylation in endothelial cells influences angiogenesis, vascular permeability, and responses to ischemic injury, while its activation in cardiac tissue can affect remodeling processes following infarction or pressure overload. Inflammatory disease models reveal roles for BMX phosphorylation in regulating immune cell functions, cytokine production, and epithelial barrier responses to inflammatory stimuli, potentially contributing to conditions ranging from inflammatory bowel disease to rheumatoid arthritis. When designing experiments to investigate these disease connections, researchers should incorporate relevant physiological stimuli (hypoxia, inflammatory cytokines, growth factors) that reflect the disease microenvironment and evaluate both acute and chronic effects of BMX phosphorylation through time-course studies and genetic manipulation approaches .